Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 44

Sort by

Sort Order Select

Journal Articles

Myeloma Cell-Derived Monoclonal Immunoglobulins Trigger IL-1β Secretion Via Inflammasome Activation in Tolerogenic Dendritic Cells

Mariko Ishibashi, Mika Sunakawa-Kii, Yoichi Imai, Hiroki Yamaguchi, Rimpei Morita, Hideto Tamura

Blood (2024) 144 (Supplement 1): 1900.

https://doi.org/10.1182/blood-2024-202957

Published: 2024

Journal Articles

SETDB1 Suppresses Interferon Responses and NK Cell-Mediated Immunosurveillance Specifically in Monocytic AML

Yu-Hsuan Chang, Keita Yamamoto, Takeshi Fujino, Teh-Wei Wang, Emi Sugimoto, Wenyu Zhang, Tomohiro Yabushita, E. Christine Pietsch, Barbara A. Weir, Ramona Crescenzo, Glenn S. Cowley, Ricardo M. Attar, Ulrike Philippar, Yutaka Enomoto, Yoichi Imai, Toshio Kitamura, Susumu Goyama

Blood (2023) 142 (Supplement 1): 713.

https://doi.org/10.1182/blood-2023-177531

Published: 2023

Journal Articles

DNAM-1/Tigit/CD155/CD112 Axis Is a Novel Target of NK-Cell Therapy in Acute Myeloid Leukemia

Yuta Kaito, Emi Sugimoto, Fumi Nakamura, Yutaka Tsukune, Makoto Sasaki, Shunsuke Yui, Hiroki Yamaguchi, Susumu Goyama, Yasuhito Nannya, Kinuko Mitani, Hideto Tamura, Yoichi Imai

Blood (2022) 140 (Supplement 1): 4514–4516.

https://doi.org/10.1182/blood-2022-164435

Published: 2022

Journal Articles

Visualization of Multiple Myeloma Mouse Model with 89 zr-Labeled Anti-CD38 Antibody By a New Imaging System; Whole-Gamma Imaging

Miwako Takahashi, Sodai Takyu, Aya Sugyo, Hitomi Sudo, Hideaki Tashima, Hidekatsu Wakizaka, Go Akamatsu, Mariko Ishibashi, Atsushi B Tsuji, Taiga Yamaya, Yoichi Imai

Blood (2022) 140 (Supplement 1): 12476–12477.

https://doi.org/10.1182/blood-2022-165050

Published: 2022

Journal Articles

Combined Inhibition of HDAC and AKT As a Strategy to Overcome Multi-Drug Resistance in Patients with Multiple Myeloma

Mitsuhito Hirano, MD, Yoichi Imai, MD PhD, Takahiko Murayama, PhD, Kota Sato, MD PhD, Junichi Yamamoto, PhD, Takumi Ito, PhD, Muneyoshi Futami, MD PhD, Masaki Ri, Hiroshi Yasui, MD PhD, Noriko Gotoh, MD, Shinsuke Iida, MD PhD, Tadao Ishida, MD PhD, Hiroshi Handa, MD PhD, Arinobu Tojo, MD PhD

Blood (2019) 134 (Supplement_1): 4325.

https://doi.org/10.1182/blood-2019-122662

Published: 2019

Journal Articles

Serum Soluble CD86, Still a Prognostic Factor in the Novel Agent Era in Multiple Myeloma Patients, Is Produced By Myeloma Cells with High CD86 Variant 3 Expression

Mariko Ishibashi, PhD, Ryosuke Kinoshita, MD, Koiti Inokuchi, MD PhD Prof., Hiroshi Handa, MD PhD, Makoto Sasaki, MD PhD, Norio Komatsu, MD PhD, Yoichi Imai, MD PhD, Norina Hiroike, MD PhD, Junji Tanaka, Sakae Tanosaki, MD PhD, Shigeki Ito, MD, PhD, Mika Sunakawa, MD, Toshio Asayama, MD, Yasuko Kuribayashi-hamada, MD, Rimpei Morita, MD PhD, Hideto Tamura, MD PhD

Blood (2019) 134 (Supplement_1): 4361.

https://doi.org/10.1182/blood-2019-124635

Published: 2019

Journal Articles

Therapeutic Targeting of Monokine Production Is a Promising Strategy to Attenuate Cytokine-Release Syndrome in CAR-T Cell Therapy

Muneyoshi Futami, MD PhD, Keisuke Suzuki, MS, Satomi Kato, BS, Yoshio Tahara, MS, Yoichi Imai, MD PhD, Takayuki Mimura, PhD, Yoshihiro Watanabe, PhD, Arinobu Tojo, MD PhD

Blood (2019) 134 (Supplement_1): 2067.

https://doi.org/10.1182/blood-2019-129601

Published: 2019

Journal Articles

Histone Deacetylase Inhibitors with or without AKT Inhibition Potentially Increase the Efficacy of Daratumumab in Multiple Myeloma By Enhancing the Antibody-Dependent Cell-Mediated and Complement-Dependent Cytotoxicity As Well As Apoptosis

Mitsuhito Hirano, MD, Yoichi Imai, MD PhD, Weng-Chit Ung, MSc, Kota Sato, MD PhD, Muneyoshi Futami, MD PhD, Arinobu Tojo, MD PhD

Blood (2018) 132 (Supplement 1): 4435.

https://doi.org/10.1182/blood-2018-99-110709

Published: 2018

Journal Articles

A Novel Mutant Wasp in X-Linked Neutropenia Partially Recapitulates Defective Neutrophil Production through Its Expression in WASP-Deficient NB4 Cells

Masayuki Kobayashi, MD, Bidisha Chanda, MD PhD, Muneyoshi Futami, MD PhD, Mizuho Yamashita, Mitsuhito Hirano, MD, Kazuaki Yokoyama, MD PhD, Yoichi Imai, MDPhD, Eigo Shimizu, Nozomi Yusa, Rui Yamaguchi, PhD, Seiya Imoto, PhD, Satoru Miyano, PhD, Arinobu Tojo, MD PhD

Blood (2017) 130 (Supplement 1): 3560.

https://doi.org/10.1182/blood.V130.Suppl_1.3560.3560

Published: 2017

Journal Articles

Successful MPB Therapy Followed By Bortezomib Maintenance for Non-Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma: Japanese Phase 2 Study - Broad-J Study

Blood (2017) 130 (Supplement 1): 5432.

https://doi.org/10.1182/blood.V130.Suppl_1.5432.5432

Published: 2017

Journal Articles

The New Immunoreceptor SLAMF3 Promotes Aggressive Biological and Clinical Characteristics in Multiple Myeloma

Mariko Ishibashi, PhD, Hideto Tamura, MD PhD, Toshio Asayama, MD, Yasuko Kuribayashi-hamada, MD, Asaka Onodera, MDPhD, Keiichi Moriya, MD PhD, Makoto Sasaki, MD PhD, Hiroshi Handa, MD PhDChief Division, Yoichi Imai, MDPhD, Norina Tanaka, MD, Junji Tanaka, MD PhD, Sakae Tanosaki, MDPhD, Shigeki Ito, MD PhD, Norio Komatsu, MD PhD, Koiti Inokuchi, MD PhD

Blood (2017) 130 (Supplement 1): 3055.

https://doi.org/10.1182/blood.V130.Suppl_1.3055.3055

Published: 2017

Journal Articles

Exploratory Introduction of Cognitive Computing to Clinical Sequencing in Hematological Malignancies

Blood (2016) 128 (22): 5262.

https://doi.org/10.1182/blood.V128.22.5262.5262

Published: 2016

Journal Articles

Clinical Profile and BRAF Status of 30 Japanese Patients with Adult Langerhans Cell Histiocytosis

Miho Ogawa, MD, Masayuki Kobayashi, MD, Koji Jimbo, MD, Toyotaka Kawamata, MD PhD, Kazuaki Yokoyama, MD PhD, Nobuhiro Ohno, MD, Yoichi Imai, MD PhD, Satoshi Takahashi, MD PhD, Arinobu Tojo, MD PhD

Blood (2016) 128 (22): 4883.

https://doi.org/10.1182/blood.V128.22.4883.4883

Published: 2016

Journal Articles

Retrospective Analysis of Treatment Outcomes for Patients with Follicular Lymphoma and Comorbidities

Aya Watanabe, Yoichi Imai, MD PhD, Kenjiro Mitsuhashi, MD PhD, Akihito Shinohara, Norina Tanaka, MD PhD, Kentaro Yoshinaga, MDPhD, Masayuki Shiseki, MD PhD, Naoki Mori, MD PhD, Junji Tanaka, MD PhD

Blood (2015) 126 (23): 5082.

https://doi.org/10.1182/blood.V126.23.5082.5082

Published: 2015

Journal Articles

Fractionated ICE with Rituximab Is Safe and Effective for Relapse/Refractory DLBCL Patients with Severe Comorbidities

Norina Tanaka, MD PhD, Yoichi Imai, MD PhD, Aya Watanabe, MD, Kenjiro Mitsuhashi, MD PhD, Kentaro Yoshinaga, MDPhD, Masayuki Shiseki, MD PhD, Naoki Mori, MD PhD, Junji Tanaka, MD, PhD

Blood (2015) 126 (23): 2713.

https://doi.org/10.1182/blood.V126.23.2713.2713

Published: 2015

Journal Articles

Prospective Analysis of Cytomegalovirus Reactivation and the Immune State of Low-Grade B-Cell Lymphoma Patients Treated with Bendamustine

Noriko Isono, MD, Yoichi Imai, MD PhD, Chihiro Asano, MD, Michihiko Masuda, MD PhD, Shigeru Hoshino, MD PhD, Keiichi Moriya, MD PhD, Hideto Tamura, MD PhD, Koiti Inokuchi, MD PhD, Shigeki Ito, MD, PhD, Yoji Ishida, MD, PhD, Toshiko Motoji, MD PhD, Junji Tanaka, MD PhD

Blood (2014) 124 (21): 4411.

https://doi.org/10.1182/blood.V124.21.4411.4411

Published: 2014

Journal Articles

Clinical Utility of Slam Family Member CD229 in Identifying Tumor Cells and High-Risk Disease Markers, CD86 (B7-2) and CD126 (IL-6 receptor), Using Flow Cytometric Analysis in Multiple Myeloma

Akiko Yamada, MD, Hideto Tamura, MD PhD, Mariko Ishibashi, PhD, Koiti Inokuchi, MD PhD, Makoto Sasaki, MD PhD, Yuriko Yahata, MD, Norio Komatsu, MD PhD, Atsushi Isoda, MD PhD, Morio Matsumoto, Hiroshi Handa, MD PhD, Yoichi Imai, MD PhD, Junji Tanaka, MD PhD, Sakae Tanosaki, MD PhD, Shigeki Ito, MD, PhD, Yoji Ishida, MD, PhD, Michiaki Koike, MD PhD

Blood (2014) 124 (21): 2063.

https://doi.org/10.1182/blood.V124.21.2063.2063

Published: 2014

Journal Articles

Interaction Between B7-H1 Molecules on Myeloma Cells and PD-1 Molecules on T Cells Induces Resistance to Antimyeloma Chemotherapy

Blood (2014) 124 (21): 2018.

https://doi.org/10.1182/blood.V124.21.2018.2018

Published: 2014

Journal Articles

Knockdown of a Wnt Receptor FZD1 reduces MDR1 /P-Glycoprotein Expression in Human Leukemia Cells through the Wnt/β-Catenin Signaling Pathway

Yan-Hua Wang, MD PhD, Toshiko Motoji, MD PhD, Yoichi Imai, MD PhD, Masayuki Shiseki, MD PhD, Kenjiro Mitsuhashi, MD, Ye Ding, MD, Junji Tanaka, MD PhD

Blood (2014) 124 (21): 2225.

https://doi.org/10.1182/blood.V124.21.2225.2225

Published: 2014

Journal Articles

MLL-HOXA9 and Calcineurin Are Novel Therapeutic Targets in Multiple Myeloma

Yoichi Imai, MD, PhD, Eri Ohta, Yanhua Wang, MD, PhD, Yukiko Kitagawa, MD, PhD, Ye Ding, MD, PhD, Osamu Yamada, MD, PhD, Yoshiro Maru, MD, PhD, Toshiko Motoji, MD, PhD

Blood (2012) 120 (21): 4007.

https://doi.org/10.1182/blood.V120.21.4007.4007

Published: 2012

NARROW

Myeloma Cell-Derived Monoclonal Immunoglobulins Trigger IL-1β Secretion Via Inflammasome Activation in Tolerogenic Dendritic Cells

SETDB1 Suppresses Interferon Responses and NK Cell-Mediated Immunosurveillance Specifically in Monocytic AML

DNAM-1/Tigit/CD155/CD112 Axis Is a Novel Target of NK-Cell Therapy in Acute Myeloid Leukemia

Visualization of Multiple Myeloma Mouse Model with 89 zr-Labeled Anti-CD38 Antibody By a New Imaging System; Whole-Gamma Imaging

Combined Inhibition of HDAC and AKT As a Strategy to Overcome Multi-Drug Resistance in Patients with Multiple Myeloma

Serum Soluble CD86, Still a Prognostic Factor in the Novel Agent Era in Multiple Myeloma Patients, Is Produced By Myeloma Cells with High CD86 Variant 3 Expression

Therapeutic Targeting of Monokine Production Is a Promising Strategy to Attenuate Cytokine-Release Syndrome in CAR-T Cell Therapy

Histone Deacetylase Inhibitors with or without AKT Inhibition Potentially Increase the Efficacy of Daratumumab in Multiple Myeloma By Enhancing the Antibody-Dependent Cell-Mediated and Complement-Dependent Cytotoxicity As Well As Apoptosis

A Novel Mutant Wasp in X-Linked Neutropenia Partially Recapitulates Defective Neutrophil Production through Its Expression in WASP-Deficient NB4 Cells

Successful MPB Therapy Followed By Bortezomib Maintenance for Non-Transplant Eligible Patients with Newly Diagnosed Multiple Myeloma: Japanese Phase 2 Study - Broad-J Study

The New Immunoreceptor SLAMF3 Promotes Aggressive Biological and Clinical Characteristics in Multiple Myeloma

Exploratory Introduction of Cognitive Computing to Clinical Sequencing in Hematological Malignancies

Clinical Profile and BRAF Status of 30 Japanese Patients with Adult Langerhans Cell Histiocytosis

Retrospective Analysis of Treatment Outcomes for Patients with Follicular Lymphoma and Comorbidities

Fractionated ICE with Rituximab Is Safe and Effective for Relapse/Refractory DLBCL Patients with Severe Comorbidities

Prospective Analysis of Cytomegalovirus Reactivation and the Immune State of Low-Grade B-Cell Lymphoma Patients Treated with Bendamustine

Clinical Utility of Slam Family Member CD229 in Identifying Tumor Cells and High-Risk Disease Markers, CD86 (B7-2) and CD126 (IL-6 receptor), Using Flow Cytometric Analysis in Multiple Myeloma

Interaction Between B7-H1 Molecules on Myeloma Cells and PD-1 Molecules on T Cells Induces Resistance to Antimyeloma Chemotherapy

Knockdown of a Wnt Receptor FZD1 reduces MDR1 /P-Glycoprotein Expression in Human Leukemia Cells through the Wnt/β-Catenin Signaling Pathway

MLL-HOXA9 and Calcineurin Are Novel Therapeutic Targets in Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only